Grant Application Handbook
Valid for the March 2024 grant round
(Open for submissions from Thursday 29 February – Tuesday 2 April 2024)

Please note that application handbooks are round specific and revised regularly.
Please ensure that you are using the correct version.
# Table of Contents

1. What type of research do we fund? ................................................................. 3  
2. Who can apply for a grant? ........................................................................... 6  
3. When can you apply? ...................................................................................... 10  
4. What funding can you apply for? ................................................................. 10  
5. How are applications assessed? ................................................................. 15  
7. Appendix 1: How to apply- completing the application form .................. 18  
8. Appendix 2: Grant Terms & Conditions ...................................................... 36
1 What type of research do we fund?

1.1 Our goal is to support research that seeks to answer the difficult questions in cancer biology. What we are looking for in an application:

Starting new ideas
We are looking for innovative research that takes intellectual risks. To us, that means helping researchers turn their bold idea into reality. And if there’s a risk of failure, we are willing to take it, if the rewards for success are worth it.

We want to see ideas which have the potential to start new lines of research and to tell us something new about cancer and how it could be prevented, diagnosed or treated.

We want to make the most of our supporters’ generous donations by funding standalone research projects. Projects should seek to answer a focused research question, not be an incremental piece of research tied to a larger programme grant.

Exciting and creative
We are looking for ideas that excite us. The ones that make us go, “I wish I had thought of that”. We are looking for proposals with a creative approach to answering fundamental questions that could change how we think about cancer. Often these are ideas that other funders may overlook.

Scientific quality
We want to see the most exciting and creative new ideas, but we are also responsible stewards of our supporters' donations. We need to see robust scientific reasoning and appropriate solid methodology to back it up. The aims of a project should be feasible with the time and resources requested, and with the expertise of the research team.

Transformative impact
We support blue-sky thinking in research and want to direct funding towards projects that could transform an area of cancer research or one day have a major impact on the lives of people with cancer. While impact on cancer patients is a priority for us and our supporters, we recognise that important discoveries take time to bear fruit and that it may be many years before the research leads to lives saved or improved.

1.2 We award grants to support fundamental or translational research into the prevention, diagnosis or treatment of cancer. We do not prioritise any field of research; we welcome research projects with a strong scientific hypothesis that draws on epidemiological, behavioural and clinical data to provide a starting point for a new avenue of research. Multidisciplinary or discipline-hopping projects are encouraged where this helps stimulate innovation.
1.3 We do not support clinical research, including clinical trials, patient care, nursing or healthcare delivery research. Neither do we support other types of applied cancer research, such as policy, public health or psychosocial research. This list is not exhaustive.

Proposals that contain a small clinical element as an essential part of a basic or translational research project are often permitted, but you are advised to contact grants@worldwidecancerresearch.org for advice before submitting your proposal.

1.4 We will consider applications in which human samples or data are used as an essential part of a basic/translational research project if the following conditions are satisfied:

- Clinical costs cannot be requested in the budget or charged to a Worldwide Cancer Research grant. This includes costs of patient or volunteer recruitment, patient expenses, the salaries of purely clinical staff, such as research nurses, honorariums or consultancy fees for clinical collaborators. It is also not acceptable to include costs for the clinical investigation, diagnosis or follow-up of patients involved in the research study.
- Projects that rely upon a large number of human samples or extensive clinical data must have this resource available through existing biobanks, databases or cohorts. Projects will not be accepted that would involve a considerable effort to recruit patients or volunteers for samples or data; Worldwide Cancer Research-funded projects must focus on conducting hypothesis-led research and not on infrastructure development. This applies equally to all types of research, including epidemiological studies.

1.5 Applications on cancer symptoms or treatment side effects are accepted only if there is a very clear link to improving cancer survival. Studies investigating the biology of a side effect or symptom alone are unlikely to be accepted.

1.6 Basic studies into fundamental cellular processes, mechanisms and molecules are within remit if the research aims to improve the understanding of cancer biology. If a project is to study the normal functioning of cellular processes, mechanisms or molecules - or to study very basic models such as yeast - evidence supporting the relevance to cancer biology must be laid out.
1.7 We need to work together to advance research quickly and support the best ideas, so we are partnering with several other cancer research funders for this grant round. This will enable more cutting-edge ideas with the potential for impact to be explored. These additional opportunities for funding are available depending on the cancer type the project focuses on or the country in which the applicant resides. We are partnering with:

![Partnership Logos]

1.8 We still welcome grant applications for projects on any cancer type and from any country. These are still encouraged to apply and will not have a reduced chance of success because of the partnerships. Importantly, working with our funding partners will allow us to fund additional projects. No additional action is needed by an applicant for a project that may be eligible for co-funding. Any successful applicants eligible for co-funding will be contacted by our Research Funding Team. More information on our partnerships can be found here: Working together to fund new cancer cures.

1.9 Our Use of Animals in Research policy states that we are committed to ensuring the animal research we fund is as robust and reproducible as possible and that the highest standards of laboratory animal welfare are met. For further details, see our Use of Animals in Research policy (https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/). If you wish to apply with an animal research project and have further questions, please get in touch with us (grants@worldwidecancerresearch.org) before you submit your proposal.
1.10 Worldwide Cancer Research grants are awarded for novel research proposals that are entirely the original work of the applicants. Any use of another investigator's work or ideas must be fully attributed to the original source. The charity reserves the right to investigate if plagiarism is suspected; this may involve the disclosure of information to third parties and the use of plagiarism-checking software. If evidence of plagiarism is found, in the opinion of Worldwide Cancer Research, the application will be immediately rejected, and the applicants may be barred from applying in future. The charity also reserves the right to inform the principal investigator (PI)’s institution. The PI takes full responsibility for the originality of the project proposal and the submission of an application constitutes acceptance of these terms by all applicants.

If you have any questions about the points above, or are in any doubt about whether your proposal will be considered within remit, please contact us (grants@worldwidecancerresearch.org) well before you submit an application.

2 Who can apply for a grant?

2.1 Our project grants are awarded to a single researcher, known as the Principal Investigator (PI) or the Grantholder. The PI is the person with the main responsibility for writing the application, and designing and directing the research project. The PI is also responsible for ensuring all requirements in this handbook and our grant terms and conditions are complied with.

2.2 The PI must be employed at a recognised, non-profit research institution. Honorary contracts and emeritus positions are usually acceptable. Researchers at commercial, for-profit organisations, e.g. biotechnology and pharmaceutical companies, cannot apply for a grant. It is also not permitted for a research institution to transfer Worldwide Cancer Research grant funds to a commercial organisation except for payment for specific services, items and reagents used in the project. This includes transferring money to spin-out companies from the laboratory or institute.

2.3 Individual scientists from commercial organisations can be named as collaborators if they provide specific expertise or reagents to the project. The nature of their involvement must be made clear. Scientists from commercial organisations cannot be co-applicants.

2.4 The PI is usually a PhD-qualified, tenured or tenure-track research group leader. Other suitably qualified persons, e.g., medical doctors, with appropriate research experience may also apply as the PI. Post-doctoral researchers with more than three years of postdoctoral research experience at the time of applying are also eligible to apply for a grant.
2.5 Post-doctoral applicants who are not yet independent principal investigators must name their group head as co-applicant on the grant. Principal investigators who have established their first research group within the past 3 years are advised to add their head of department as a co-applicant. All co-applicants, group heads or heads of departments must have a minimum contribution of 5%, which could be as a mentor.

2.6 You cannot apply to Worldwide Cancer Research for a project grant (either as a PI or co-applicant) if you are currently applying for, or have received, funding from the tobacco industry or bodies substantially funded by the tobacco industry, within the last 10 years. For further information see our policy section at https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/.

2.7 PIs working in groups or at institutes that receive long-term, or core research funding may apply for a grant, but only for a research project that is clearly distinct from that supported by the other funding. Before a grant is awarded, we will request documents relating to the other funding to confirm there is no overlap with our award.

2.8 The PI’s research institution must be able to accept the terms and conditions within our grant contract, which can be found in Appendix 2 of this handbook. The grant contract is not negotiable except in the rare situation that a clause conflicts with local or national law. Applying to Worldwide Cancer Research is taken as an agreement to the terms of our grant contract. Therefore, PIs must ensure the relevant grant or finance officer at their institution has reviewed the contract in detail before an application is submitted. If an institution is unable to agree to the terms of the grant contract when an offer is made, the offer will be withdrawn.

2.9 The PI must have a contract of employment that will last for at least the duration of the grant requested or be able to show evidence that their current contract would be extended if the grant were awarded.

2.10 A research group can only submit one application per grant round. For example, if you are the PI on an application, no member of your research group can be a PI on a second application in the same round. You or another member of the same research group can be a co-applicant or collaborator on other applications in the same grant round. If, at any stage of a grant round, multiple PIs are found to be from the same research group, all the applications will be rejected immediately, and the group may be barred from applying in the future.

2.11 If the principal investigator on an application is rejected at the preliminary triage review stage of a grant round, they can submit applications in subsequent grant rounds, so long as the research proposal is sufficiently different (at least 50%) from the research proposal that was rejected at preliminary triage review. This will be assessed by our Scientific Advisory Committee and their decision is final.
2.12 If you wish to re-submit a project (or one very similar) that has been rejected in the most recent grant round, but had passed preliminary triage review, you can re-apply as a ‘resubmission’ in the next grant round. You will be asked to address any previously provided feedback. Note that resubmissions are considered in equal competition with all other applications in the round and are not guaranteed to pass preliminary triage. You may only resubmit a project once.

2.13 If the Scientific Advisory Committee formally invites a grant to be resubmitted in a revised form, you may submit it in the next grant round. These are called ‘invited resubmissions’. Invited resubmissions are guaranteed to pass preliminary triage and will go out to external peer review. Invited resubmissions will be discussed at the Scientific Advisory Committee meeting. Projects are only re-invited once, and the principal investigator cannot re-submit the same project to Worldwide Cancer Research after that.

2.14 If the principal investigator submitted a continuation application or resubmission in the most recent grant round and it was not funded, they can submit a new application in the following grant round.

2.15 If the principal investigator on an application is successful in a grant round, they cannot apply in the next grant round as a PI but can apply in the following grant rounds. They can, however, apply in the next grant round as a co-applicant. Please note that successful co-applicants can apply in the next grant round either as principal investigators or co-applicants.

2.16 If the principal investigator has previously applied for funding from Worldwide Cancer Research, any ‘new’ application submitted must have a sufficiently different (at least 50%) research proposal compared to any of their previous proposals.

2.17 Other senior researchers who would be substantially involved in managing the project can be included as co-applicants. **Co-applicants should be at senior post-doctoral level or above** (i.e., with greater than 3-years of post-doctoral research experience at the time of application). Co-applicants do not need to be at the same institution as the PI.

2.18 Where a project is collaborative and involves more than one investigator and/or research institution, one of the applicants must take the role of PI. This must be the investigator whose research group will carry out most of the work on the project.

2.19 If an award is made for a collaborative project, it will be made entirely to the PI’s institution. It is the host institution’s responsibility to put in place an arrangement to reimburse costs incurred by other institutions during the project. **Worldwide Cancer Research takes no responsibility for ensuring the costs of collaborating laboratories are reimbursed.**
2.20 You may apply to other organisations at the same time as Worldwide Cancer Research for funding to support the same project. However, we must be informed of any such 'parallel' applications in the relevant section of the application form.

2.21 If you choose to submit parallel applications to fund the same project and are offered a grant by both Worldwide Cancer Research and another organisation, you will be asked to choose which grant to accept. You are not permitted to double-fund a project or use your Worldwide Cancer Research grant for a different programme of work than that described in the grant application.

2.22 In rare cases, where a parallel award is much smaller than the Worldwide Cancer Research grant, a PI may be permitted to keep both grants with an appropriate reduction in budget to remove any overlap in funding.
3 When can you apply?

3.1 Once registered on our grant system, you can begin preparing an application when a grant round opens. The 2024 grant round will open on Wednesday 14th February 2024. Completed applications can only be submitted during the submission period, Thursday 29th February until Tuesday 2nd April 2024. Please note that unsubmitted or deleted applications will be permanently deleted from our system after 30 days of the submission closing date.

3.2 Worldwide Cancer Research will only accept the first 500 applications submitted in the grant round.

3.3 For the 2024 grant round, applications must be submitted by 17:00hrs (British Local Time) on Tuesday 2nd April 2024

3.4 You are advised to allow plenty of time to submit your grant application. It must be approved by your Head of Department and Authorising Officer before the grant deadline. We will not extend the deadline to allow these approvals to be completed, or because of any confusion about how the online grants system works. Grant deadlines will only be extended if we accept fault for causing an unreasonable delay to your submission, e.g., because of a verified technical failure in the online grants system.

3.5 We cannot guarantee to respond before the grant deadline to any queries sent less than 48 hours before the deadline, although we will try to do so. Please remember that we are based in the UK.

3.6 Successful applications submitted to the March 2024 grant round will be offered a grant starting from 1 January 2025. We may allow the start date to be deferred by up to 3 months, providing our prior approval has been sought.

4 What funding can you apply for?

4.1 Worldwide Cancer Research offers grants for 1-3 year research projects. Grants cover the direct costs of the project, including research consumables, the salaries of research staff working directly on the project, travel to conferences or to visit collaborators, and any essential services or small pieces of specialist or unusual equipment. For a more detailed description of eligible budget items, please see Table 1.

4.2 The host institution must cover all indirect and overhead costs. This is not negotiable even if it is standard practice for your institution to charge overheads to external grants.

4.3 The maximum budget permitted is £275,000, but it should be noted that most of our 3-year grants have a budget of about £200,000.
4.4 You must submit a research proposal that describes a discrete project achievable within the duration of the grant and with the financial support requested. Applications which describe a large programme of work – for example, the work of an entire laboratory – and then request a contribution towards it, will be rejected. The grant budget must reflect the work described in the research proposal.

4.5 We will not accept applications where it appears that the main purpose of applying for funding is the purchase of equipment or the development of research infrastructure such as tissue banks, patient cohorts or databases. Some specialist equipment or infrastructure development can be included in a Worldwide Cancer Research grant, but only as a small, essential part of a hypothesis-led research project. Projects that concern research in which the main body of work is computational can request data storage and computing power or computing time costs when well-motivated and justified.

4.6 PhD student salaries/stipends can be included in a project grant budget. Note that project grant applications which include a PhD student will be assessed only on the scientific strength of the project, not on the educational benefits for the student.
Table 1: Constructing your budget – what can you charge to a Worldwide Cancer Research Grant?

<table>
<thead>
<tr>
<th>Staff Salaries</th>
<th>Permitted</th>
<th>Not Permitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>o One (occasionally two) research staff who will be employed specifically to work on the project.</td>
<td>o No more than 2 full-time salaries can be requested.</td>
<td></td>
</tr>
<tr>
<td>o This can be any type of research staff, e.g., post-doc, PhD student, technician, graduate research assistant, clinician scientist, etc. The salary justification MUST detail why a staff member with a specific level of experience is requested, referencing the experimental plan and the skill level needed. If a person is named, please explain why they were chosen.</td>
<td>o You cannot request the salary or partial salary for anybody who has a tenured, tenure-track or open-ended post, or whose salary is guaranteed and funded by the institution in another way unless you can demonstrate that the person’s time will be dedicated to the project.</td>
<td></td>
</tr>
<tr>
<td>o Degree fees can be requested along with stipend support for PhD Students (the total amount should be entered in the Gross Salary section and breakdown details given in the justification).</td>
<td>o We do not under any circumstances offset the salaries of people employed by the institution as core support staff (e.g., technicians). If fees have to be paid for core services provided within the institution (e.g., statistics, bioinformatics, sequencing services) then include these fees under ‘Other’, not in the salary section.</td>
<td></td>
</tr>
<tr>
<td>o Please account for any annual increases for inflation or projected pay awards in the requested salaries and note that the grant commences in the next calendar year.</td>
<td>o The salary of the PI cannot usually be requested. The only exception to this rule is detailed on the left.</td>
<td></td>
</tr>
<tr>
<td>o If you intend to have a full-time researcher 100% committed to the project whose salary is covered by another funding source, but would like to request research consumables, you must name the researcher in this section. Please put £0 as the requested salary, explain why the researcher is ideal for the project, and provide details of the funding source. The funding source must only be contributing salary (e.g. PhD scholarship).</td>
<td>o Purely clinical staff, e.g., research nurses involved in patient recruitment, cannot be included in the salary budget.</td>
<td></td>
</tr>
<tr>
<td>o The PI’s salary can be requested only if the PI is a post-doctoral researcher with 3-10 years post-doctoral experience who is trying to establish independence. A mentor (either the Head of Department or a Research Group Head) must be named as a co-applicant in this case.</td>
<td>o We do not cover the cost of recruiting staff members.</td>
<td></td>
</tr>
</tbody>
</table>
### Research Consumables

<table>
<thead>
<tr>
<th>Permitted</th>
<th>Not Permitted</th>
</tr>
</thead>
</table>
| **Our total standard consumables allowance is £15,000 per year** for each researcher working full-time (100% committed) on the project. This covers routine research consumables e.g., glassware, plasticware, tissue culture, molecular biology, and immunohistochemistry. | o Do not include unusual, high-cost or non-consumable items in the consumables section – these should be listed in the budget section headed ‘Other’.  
| o If you are requesting the salary of a researcher who is not working full-time (100% committed) on the project, you are entitled to request the commitment % of the £15,000 per year consumables allowance. For example, if you are requesting the salary for a researcher working 60% on the project, you are entitled to claim £9,000 per year (15,000 × 0.6). | o Consumables for research positions not listed in the salaries section cannot be claimed.  
| o You can request consumables for a full-time researcher whose salary is covered solely by another funding source **only if they are 100% committed** to the project. Please see the Staff Salaries section for details. | o Research consumables totalling over £30,000 per year.  
| o You must break down your consumables’ request under at least 3 general headings (using the “Add Consumable” button), for example ‘tissue culture’, ‘PCR’, ‘immunohistochemistry’. |  
| o In exceptional cases, the standard allowance can be increased to £30,000 a year if the project requires **two full-time** members of staff. | |

### Animals

<table>
<thead>
<tr>
<th>Permitted</th>
<th>Not Permitted</th>
</tr>
</thead>
</table>
| o Costs for the purchase, importation, housing and maintenance of animals can be included in your budget. | o Animal research licences/certification and training courses are not eligible costs.  
| o There is no maximum animal budget. All animal costs must be justified. Animal costs higher than £10,000 per year must be well justified. | |

### Equipment

<table>
<thead>
<tr>
<th>Permitted</th>
<th>Not Permitted</th>
</tr>
</thead>
</table>
| o Funds can be requested for small pieces of specialist or unusual equipment that are essential for the project. | o Standard office computers (with one exception, see left) and tablets cannot be included on the grant.  

Small pieces of routine equipment can be included only if the PI is a new group leader within the first three years of setting up their first laboratory.

If the PI is based at an institute in a low- or middle-income country (https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/daclist.htm), they can request routine equipment regardless of their seniority level.

One laptop/computer per full-time researcher who will be 100% committed to the project may be requested. This is allowed only if it is essential to the project (e.g., required for data processing) and not standard computer work (e.g. data analysis, writing papers etc.).

Equipment should usually be purchased at the start of the project.

Standard equipment that ought to be available in most research institutions e.g., pipettes, refrigerated centrifuges, PCR machines, gel apparatus (with one exception, see left) are not admissible.

We do not offer equipment grants. Do not request large, expensive items of equipment that take up most of the grant budget. Your application will be rejected.

### Travel

<table>
<thead>
<tr>
<th>Permitted</th>
<th>Not Permitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funds for conference registration/travel can be requested. The standard allowance is £500 per year, for each full-time researcher whose salary is paid by the grant.</td>
<td>No conference registration/travel funding can be requested for any staff whose salaries are not paid by the grant, including the PI and co-applicants.</td>
</tr>
<tr>
<td>Funds for other travel can also be requested, e.g., visits to collaborating laboratories or travel for patient and public involvement, but these must be itemised separately to conference travel and well justified.</td>
<td></td>
</tr>
</tbody>
</table>

### Other

These costs usually fall into the following categories:
- High-cost items or experiments, e.g., microarrays or SILAC.
- Fees for external or internal services, such as antibody production, DNA sequencing or statistics support.
- Specialised software specific to the proposed research is permissible. This should not include standard software licenses (e.g. Microsoft Office, GraphPad).
- Data storage and/or computing time costs may be included in the application. This is only allowable for projects that anticipate generating a lot of data. This must be well justified.

Do not include:
- Publication costs. We have a separate fund to support the costs of open access publishing – https://www.worldwidcancerresearch.org/for-researchers/our-research-policies/
- Institutional overheads and indirect costs, including equipment maintenance, journal subscriptions, secretarial support, advertising, recruitment, postdoctoral training, office stationery, etc.
- Clinical costs. This includes the costs of patient/volunteer recruitment, the investigation, diagnosis, treatment or follow-up of patients providing samples for a research study, and honorarium or consultancy payments to clinical collaborators.
5 How are applications assessed?

5.1 After the grant deadline, all applications are checked by the Research Funding team to ensure they have been completed correctly and that all the required information has been supplied. Applications requiring minor changes may be returned for amendment, but those with major omissions or errors will be rejected without further review.

5.2 If your application is returned for administrative changes, it has not yet been checked for compliance with our research funding strategy and policies. The return of your application for changes does not imply that your application has been judged to be within our funding remit and accepted for scientific review.

5.3 Applications are reviewed by senior members of the Research department to ensure they comply with our funding strategy and policies. Any applications which do not comply will be rejected without further review. Please note the Worldwide Cancer Research funding remit is always interpreted conservatively.

5.4 The first round of scientific review is a preliminary triage by our Scientific Advisory Committee (SAC). Each application is allocated to the two committee members most suitable to review it, and they judge whether it meets our research strategy criteria (see Section 1) and is likely to be competitive for funding. If both SAC members agree an application does not meet the criteria or is not competitive, then it is rejected (triaged) without further review.

5.5 When preliminary triage is complete, applicants rejected at this stage will be notified by email. There will be no feedback available for applications rejected at preliminary triage and the committee’s decision is final.

5.6 The current membership of the Scientific Advisory Committee is:

Dr Olivia Rossanese, The Institute of Cancer Research, London, England (Chair)
Dr Renata Basto, Curie Institute, Paris, France
Professor Adrian Bracken, Trinity College Dublin, Republic of Ireland
Dr Aura Carriera, Severo Ochoa CSIC, Madrid, Spain
Professor Petr Cejka, Institute for Research in Biomedicine, Bellinzona, Switzerland
Professor Jonine Figueroa, NCI, Shady Grove, United States
Dr Pim French, Erasmus Medical Center, Rotterdam, Netherlands
Dr Vincenzo Giambra, Fondaizone IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Dr Maite Huarte, University of Navarra, Spain
Dr Sheeba Irshad, King’s College London, England
Professor Yogesh Kulathu, University of Dundee, Scotland
Applications which are kept in the round after preliminary triage are then sent to external peer review. We aim to secure at least three external reviews for each application.

External reviewers are asked to assess applications on the following criteria:

- **Relevance** – Is the proposed research relevant to cancer? If successful, will the results contribute significantly to our understanding of cancer or fundamental biology relevant to cancer, or to the translation of such research into clinical benefit?
- **Originality** – Is the proposed research addressing new and interesting questions that we currently do not have answers to? Are the results of other groups working in this area likely to make this proposal redundant?
- **Experimental design** – Is the proposed research project and the experiments described in the application designed appropriately to answer the questions being addressed?
- **Applicant** – Does the track record and scientific ability of the applicant(s), as reflected in their CV(s), give confidence that they will be able to carry out the proposed research project successfully?
- **Achievability** – Is the proposed research project achievable with the resources requested in the application and the other resources that the applicant(s) have indicated will be available?

All applications that include proposals to use mammals with special protection under UK law (cats, horses, dogs and non-human primates) will undergo an additional layer of peer review by the UK’s National Centre for the 3Rs (https://www.nc3rs.org.uk/) for an expert assessment of animal welfare. Our full Use of Animals in Research policy is available at https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/
5.10 All applications that are externally peer reviewed are assessed by the Scientific Advisory Committee. They will conduct a secondary triage to further remove any applications that have no prospect of being funded. The remaining applications will be discussed, scored and ranked at the Scientific Advisory Committee meeting. Alignment with our research strategy will also be considered.

5.11 Applications are awarded funding based on the ranked list until the allocated funds are spent. Inevitably, some high-quality projects with good reviews will not be funded due to limited funds.

5.12 Successful applicants will be notified by email as soon as possible after the Scientific Advisory meeting and asked to confirm informally they will be accepting the grant. The grant award agreement will follow soon after; the grant cannot be activated until we have received a signed copy of the agreement.

5.13 Unsuccessful applicants will usually be notified within one month of the Scientific Advisory meeting.

5.14 Where external referees have provided comments to be fed back to the applicant, we aim to provide these (to both successful and unsuccessful applicants) within a month of the Scientific Advisory meeting. Please note that the referees’ views may vary markedly from each other, and funding decisions are not made solely on external reviews. We will not enter a debate regarding the content of these reports.

6 Questions? Contacting Worldwide Cancer Research
Please send all queries to the Research Funding team email address: grants@worldwidecancerresearch.org

If you wish to speak with someone urgently, our main office number is +44 (0)300 777 7910.
Appendix 1: How to apply- completing the application form.

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.1 Registration</td>
<td>19</td>
</tr>
<tr>
<td>7.2 Manage My Details</td>
<td>19</td>
</tr>
<tr>
<td>7.3 My Research Outputs</td>
<td>20</td>
</tr>
<tr>
<td>7.4 Eligibility Questions and Diversity and Inclusion Survey</td>
<td>20</td>
</tr>
<tr>
<td>7.5 Research Details page</td>
<td>20</td>
</tr>
<tr>
<td>7.6 Principal Investigator page</td>
<td>22</td>
</tr>
<tr>
<td>7.7 Additional Information</td>
<td>22</td>
</tr>
<tr>
<td>7.8 Co-applicants page</td>
<td>23</td>
</tr>
<tr>
<td>7.9 People Involved page</td>
<td>23</td>
</tr>
<tr>
<td>7.10 Inappropriate Reviewers page</td>
<td>24</td>
</tr>
<tr>
<td>7.11 Head of Department page</td>
<td>24</td>
</tr>
<tr>
<td>7.12 Authorising Officer page</td>
<td>25</td>
</tr>
<tr>
<td>7.13 Research Summary page</td>
<td>26</td>
</tr>
<tr>
<td>7.14 Financial Details page</td>
<td>26</td>
</tr>
<tr>
<td>7.15 Project Description page</td>
<td>30</td>
</tr>
<tr>
<td>7.16 Alignment with our Research Strategy</td>
<td>31</td>
</tr>
<tr>
<td>7.17 Animal research</td>
<td>31</td>
</tr>
<tr>
<td>7.18 Intellectual Property</td>
<td>32</td>
</tr>
<tr>
<td>7.19 Other Funding page</td>
<td>33</td>
</tr>
<tr>
<td>7.20 Attachments page</td>
<td>33</td>
</tr>
<tr>
<td>7.21 Declaration page</td>
<td>34</td>
</tr>
<tr>
<td>7.22 Validation page</td>
<td>34</td>
</tr>
</tbody>
</table>
This section gives practical guidance about filling in the grant application form. It is important that you first read the earlier part of the handbook to ensure that your project proposal is within remit, that you are eligible to apply, and that you prepare your budget according to our requirements. Failure to follow the regulations laid out in this handbook may result in your application being rejected.

All applications must be completed in English.

7.1 Registration

Applicants must register on the Worldwide Cancer Research grant system, which can be found at https://grants.worldwidecancerresearch.org. When completing your registration, please do not use BLOCK CAPITAL letters for your name, institution, and/or country.

If your institution does not appear in the drop-down list as part of the registration process, please contact Worldwide Cancer Research (grants@worldwidecancerresearch.org), providing details of your institution and proof of the non-profit status of the organisation so that it can be added to our database.

All registrants are required to use their personal, institutional email addresses (not generic accounts) and not commercial webmail such as Gmail, yahoo, Hotmail, etc.

Application participants such as the Head of Department, Authorising Officer and any Co-Applicants must also register on the grant system if they have not previously done so. If application participants are already registered on the grant system, you can add them by searching for their email address.

Registration can be performed at any time throughout the year and, as the PI, you must check with the other application participants that they have registered on our grants system before you try to add them to your online application.

We request that you do not share your login details with other people. You will be held responsible for all activity performed under your account.

We recommend that you use Chrome or Safari browsers when using the grant system.

7.2 Manage My Details

To complete an application, you need to fill in the Basic Information and CV sections of Manage My Details. This information is automatically used to populate some of the Principal Investigator section of the application.

All Co-applicants need to register on the Worldwide Cancer Research online grants system and fill in the Basic Information and CV sections of Manage My Details. This information will automatically populate the Co-applicant CVs in the application form.

Please leave the end date of your current employment blank on the CV.
Please ensure the CVs of the PI and Co-applicants are completed in full. Incomplete applications may be rejected without review.

7.3 My Research Outputs

You can search for and import your publications using Europe PMC in this section. If you are unable to import your publication, you can enter its details manually using the ‘New’ button. A window will open where you can enter the ‘Title’ of your publication. Please DO NOT enter Authors names, Journals or Publication dates on this page. Once you have pressed the ‘Save’ button, you will be automatically directed to your Research Output, where you will be able to enter Authors, Journal and Publication date by clicking on ‘Journal’ or ‘People’ respectively from the left-hand panel and pressing on ‘Add Journal’, ‘Add Person’. In case your publications includes a long list of authors, please include the first 3 authors and the last author.

Do not include abstracts or scientific summaries in your publication list.

There will be a section later in the application where you will provide the total number of your publications (your entire publication record). You will also be able to select the 10 most recent, relevant publications for your application.

7.4 Eligibility Questions and Diversity and Inclusion Survey

Before you can start your application, you will have to answer a few questions to determine whether you are eligible to apply for our funding. If you are eligible, you will be directed to a diversity and inclusion survey. Please note that once you have filled out the eligibility form, you have to click ‘Save’ before you can submit it.

The collection of diversity and inclusion data, e.g., age, health, ethnicity, gender, and nationality, is for monitoring purposes only. This data will be treated as strictly confidential and will not be used in any way that allows individuals to be identified. Once this is completed, you will be able to start your application.

If you would like to know more about the data that we collect, please refer to our research funding privacy notice (https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/).

7.5 Research Details page

Title of Project
The maximum permitted length for the project title is 250 characters (including spaces). **Do not use BLOCK CAPITAL letters unless it is scientifically required.** To use Greek letters, create them in Word using the insert symbol function, then cut and paste into the project title box.

The project title should give potential referees a clear idea of the proposed research (e.g., Epigenetic influences on FGFR2 signalling in colorectal carcinoma). Avoid novel acronyms and general titles (e.g., Using ARIST to study cancer). You should also avoid including any
commercially sensitive or confidential information in the title, as this title will be used by Worldwide Cancer Research publicly if the grant is awarded.

If this is a resubmission (either invited or uninvited), you should preferably use the same title as the original application.

Institution where grant will be held
This is the institution where most of the research will be conducted and where the PI will be working.

First, select the country in the Country Filter box: type any part of the country name and select from the drop-down list. Then do the same for the institution itself.

If your institution is not on the list, please contact Worldwide Cancer Research (grants@worldwidecancerresearch.org) so that it can be added to our grants system.

Department or Unit
Please enter the main department or unit - not the name of your research group - e.g., Department of Cancer Biology, Department of Immunology.

City and Country
Worldwide Cancer Research funds research in many different countries and a) some institutes (e.g., INSERM in France) have many different locations within one country or b) the same names (e.g. National Biomedical Research Centre) are used in many different countries. For these reasons, we request you enter the city and country to confirm the correct institution is identified.

Duration
The duration of the project can be between 12 and 36 months.

Type of Application
New Application – if your application does not fall into one of the other categories listed below, select this option.

Resubmission – select this if you have applied to us with a similar project that was rejected after preliminary triage in the previous grant round. You will be required to complete the details of the previous application. Note that resubmissions are considered in equal competition with all other applications in the round and are not guaranteed to pass preliminary triage. You may only resubmit once.

Invited Resubmission - Only select this if you were formally invited to resubmit an application and our Research Funding team instructed you to select 'Invited Resubmission'. You will be required to complete the details of the previous application. Invited resubmissions are guaranteed to pass preliminary triage and will go out to external peer review. Invited resubmissions will be discussed at the Scientific Advisory meeting.

For both types of resubmissions, you are offered the option of attaching a PDF document (maximum length 2 pages) to respond to any previous comments made by the external referees and/or the Scientific Advisory Committee.
7.6 Principal Investigator page

Principal Investigator Details, Qualifications, Employment

These sections should automatically populate with the information you have supplied in Manage My Details (Basic Information and CV). If anything is incomplete or incorrect, please ‘Save and Close’ the application and amend the information in Manage My Details. It is important to show you meet our eligibility criteria in terms of qualifications and research experience.

Publications

Please choose the 10 most recent, relevant publications from the dropdown list provided by pressing the ‘ ‘ button. This list is automatically populated with the information you have supplied in the My Research Outputs section. If anything is incomplete or incorrect, please ‘Save and Close’ the application and amend the information in My Research Outputs. You are allowed to include publications on pre-print servers, such as BioRxiv.

Early Career Principal Investigator

You will be asked if you are currently a post-doctoral researcher or a principal investigator who has established their first research group/lab within the past 3 years. Please note that this is for internal monitoring only and will not appear on the application form that is reviewed by our Scientific Advisory Committee or external peer reviewers.

There is also a question about how you heard about our grant round. This is for monitoring purposes only and will help us promote our grant rounds in the future.

7.7 Additional Information

Worldwide Cancer Research acknowledges that your qualifications and publication lists do not always reflect all your work. This section allows you to highlight any further contributions you make to the research community (such as the development of research tools; public engagement and contributions to the wider society, etc). This is also an opportunity to describe how the COVID-19 pandemic or other factors (such as career breaks, parental leave, etc) may have affected your academic work and impacted your career, your research outputs, or your ability to deliver research. Please do not use this section to add your publications.

PLEASE NOTE that this section is optional and by completing it you are consenting to the information being shared with external peer reviewers and our Scientific Advisory Committee. Applicants are asked to only disclose information that they are comfortable with being shared with the reviewers. For more information on how we collect, store and process personal information as part of our research grant application and award management activities, our Research Funding Privacy notice can be found here.
7.8 Co-applicants page

You can include up to three Co-applicants. Co-applicants should be experienced researchers (i.e., with more than 3-years post-doctoral research experience or equivalent) who have a significant role in the design or management of the project. They can be from any institution and any country, but scientists from commercial organisations cannot be Co-applicants. Individual scientists from commercial organisations can be named as collaborators if they provide specific expertise or reagents to the project.

Post-doctoral applicants who are not yet independent principal investigators must name their group head as Co-applicant on the grant. Principal investigators who have established their first research group within the past 3 years are advised to add their head of department as a Co-applicant. A Co-applicant must have a minimum contribution of 5%, which could be as a mentor.

All Co-applicants must already be registered to use the online grants system. Registration can be performed at: https://grants.worldwidecancerresearch.org. To identify application participants in our database, you will need to know the exact email address they used to register on the Worldwide Cancer Research grants system.

The Co-applicant’s role in the application is as follows:
1. When you have added a Co-applicant, they will be sent an email inviting them to confirm their participation in the application, to enter or update their CV and to complete their ‘Grant contact publication’ form.
2. After confirming their participation, the Co-applicant will then be given access to their ‘Grant contact publication’ form where they add and submit their publications. Only the 10 most recent, relevant publications should be included, and it is the responsibility of the Principal Investigator to ensure that the Co-applicant completes the form before submission.
3. When the application has been completed by the PI, Co-applicants must approve the application for submission. They can view the PDF of the application but cannot edit it.

Please note that the PI cannot submit the application until each Co-applicant has completed all of the above.

CVs for all Co-applicants are mandatory; they appear in the full application PDF that is sent to reviewers. CVs can be viewed in the Scientist Information section of the application PDF.

There are no restrictions on how often or how many times someone can be a Co-applicant in a single grant round.

7.9 People Involved page

This page is designed to show the contribution of people who will be involved with the project.

Percentage time for Principal Investigator and Co-applicants
Indicate what percentages of their time these people will devote to this project.
People in your research group
List the people within your immediate research group who will be working on this project up to a maximum of 3 people (apart from the PI and any Co-applicants). Please DO NOT INCLUDE anyone who will be listed as a named staff member in the Financial Details section.

Use the “Job Title” field to state the position of the person involved (e.g., PhD student, Technician, Postdoc). Use the “Role/Activities” field to describe the person’s contribution to the project (e.g., skills, tasks, techniques). Please state the source of funding for each person's salary.

You will be asked to upload a short CV (maximum of 3 pages) for any staff member who has a PhD (or equivalent) qualification.

**Listing too many people for the work proposed may be regarded negatively as our grants are for discrete projects rather than research programmes with large teams of staff.**

Collaborators
We do not request information about the amount of time that each collaborator will contribute to the project as it is assumed that it will be less than 5% of their time. List the people outside your immediate research group who will be working on this project (apart from Co-applicants). You can only list up to four collaborators - if this is a problem, please contact us.

Collaborators are those people whose involvement is limited to supplying strains or reagents, expertise or advice in a particular experimental technique or area of science or providing other specific but limited input.

We do not require CVs for collaborators, and they do not need to use the online grants system to indicate their agreement. However, we do require you to attach either an email from the collaborator or a scanned letter of agreement using their institutional headed paper. The email/letter should be signed (if a letter) and dated within the last three months; it MUST include details of their contribution to the project and reference the Worldwide Cancer Research application, specifying the grant round and project title. If you are attaching an email, it must contain full message headers. There should be a separate email/letter from each individual collaborator.

**7.10 Inappropriate Reviewers page**

If you consider that someone would not be able to provide an impartial review of your research proposal, or you have other good reasons for not wanting them to see the proposal, you can list them as an inappropriate reviewer.

Reasons such as “main scientific competitor” and “commercial sensitivity” are acceptable. Note that this section will be seen by the external referees and the Scientific Advisory Committee. **A maximum of 4 inappropriate reviewers can be listed.** DO NOT simply list all the main groups working in your field. Such blanket attempts to exclude all expert reviewers will be ignored.

**7.11 Head of Department page**
The Head of Department (or equivalent) of the institution where the grant will be held, must:

a) participate in this application
b) approve the submission of this application.

Your Head of Department must already be a registered user of the online grants system (please refer to Section 7.1). Registration can be performed at: https://grants.worldwidecancerresearch.org and your Head of Department should complete the CV section in their account. If application participants are already registered on the grant system, you can add them by searching for their email address.

Participating in the application allows the Head of Department to view the PDF of the application, but not edit it. The applicant cannot submit the application until both the Head of Department and Authorising Officer, along with all Co-applicants, have agreed to participate.

NB: The approval of the submission by the Head of Department and Authorising Officer is the final step in the application process. After the applicant clicks the Submit button, the Head of Department has to approve the submission and then the Authorising Officer has to approve it, in that order. The Head of Department and Authorising Officer cannot be the same person. It is only after they have both done this that the application is officially submitted. **This must happen before the application deadline; we will not extend the deadline to allow these approvals to be made.**

The approval of the application by the Head of Department and Authorising Officer confirms that the Institution agrees with the budget requested by the applicant and with the Worldwide Cancer Research grant application terms, conditions, procedures, and grant contract, as described in this issue of the Application Handbook.

The Principal Investigator and the Head of Department can be the same person.

7.12 Authorising Officer page

The application must be approved by an Authorising Officer, normally the Finance Officer or Research Officer (or equivalent) of the institution where the grant will be held. They must:

a) participate in this application
b) approve the submission of this application.

Your Authorising Officer must already be a registered user of the online grants system (please refer to Section 7.1). Registration can be performed at: https://grants.worldwidecancerresearch.org. Registration using general office accounts is **not** permitted. If application participants are already registered on the grant system, you can add them by searching for their email address.

Participating in the application allows the Authorising Officer to view the PDF of the application, but not edit it. The applicant cannot submit the application until both the Head of Department and Authorising Officer, along with all Co-applicants, have agreed to participate.

NB: The approval of the submission by the Head of Department and Authorising Officer is the final step in the application process. After the PI clicks the Submit button, the Head of Department
has to approve the submission, followed by the Authorising Officer, in that order. The Head of Department and Authorising Officer cannot be the same person. It is only after they have both done this that the application is officially submitted. This must happen before the application deadline. We will not extend the deadline to allow this approval to be made.

The approval of this application by the Head of Department and Authorising Officer confirms that the Institution agrees with the budget request and with Worldwide Cancer Research grant application terms, conditions, procedures, and grant award agreement, as described in this issue of the Application Handbook.

The PI, Head of Department and Authorising Officer must normally be three separate people, but Head of Department and PI can be the same. The Authorising Officer cannot have any other role in the application. If this causes any problems, please email grants@worldwidecancerresearch.org

7.13 Research Summary page

On this page you need to provide a) a scientific abstract (max. 300 words) and b) a lay summary (250 words). The scientific abstract will be shared with potential external peer reviewers and may be shared with potential co-funders, together with your name, institution and project title. The scientific abstract may influence external peer reviewer decisions to review.

If the scientific abstract contains commercially sensitive or otherwise confidential information, please tick the ‘confidential’ box. You will be asked to provide a non-confidential abstract that, if your application is successful, will be published on the International Cancer Research Partnership website: https://www.icrpartnership.org/

The lay summary must be suitable for the general public – we suggest that you write it as if it were a short scientific story in a newspaper. Do not use technical language or jargon. If possible, we would recommend that you ask a non-scientific person to review the lay summary. If your application is successful, your lay summary will form the basis of what will go on the Worldwide Cancer Research website which you can access here: http://www.worldwidecancerresearch.org/research/projects. We will also ask for your photo to go with the summary.

Lay summaries may be used for a variety of fundraising and marketing activities, including our bi-annual supporter newsletter, fundraising leaflets, competition mailings and on our website. We may also use the information and photos after your grant has ended, for example, when communicating the outcomes of the project after publication of manuscripts.

7.14 Financial Details page

Before completing this section, please ensure you have read section 4 of this handbook, which details the costs that are permitted within a Worldwide Cancer Research grant budget. Grants containing ineligible budget items will have these items removed without discussion and may even cause the grant to be rejected.
**Staff Costs**

You must only ask for the staff you need to perform the tasks in the proposed project. Our Scientific Advisory Committee takes a view on whether a project needs 1 or 2 dedicated researchers and awards the corresponding number of posts.

If your application is successful:

- You will not be permitted to use up any surplus salary budget on extra posts not originally in the application
- The salary requested for the desired position (except in extenuating circumstances) is not subject to modification
- Any salary budget remaining once you have recruited the posts that were awarded on the grant cannot be used to pay for other staff or transferred to other budget categories.

Any requests for staff changes following the initiation of a grant must be scientifically justified and approved by Worldwide Cancer Research. We understand that changing scientific needs of the project may come to favour a different staffing arrangement than that originally applied for.

a) **Staff Member**

Please specify (Yes/No) if there is a named candidate for the post. If “Yes”, you will be asked to provide the name of the candidate and upload a copy of their CV (unless their CV has been uploaded in another section of the application). If the post is to be advertised, you should select “No” and proceed to provide information on the post for which you are requesting funding.

Please provide details of the type of staff member (e.g., graduate research assistant, PhD student, postdoctoral, technician or other), their position and the time they will spend on the project. Staff members employed and salary paid by Worldwide Cancer Research are expected to be working full-time on the project (100% committed). If the staff member will be employed on the project less than 100% of their time or you are requesting less than 100% of their salary, this should be explained in the justification section.

If you wish to have a full-time staff member 100% committed to the project whose salary is covered by another funding source, but would like to request research consumables, you must name the staff in this section. Please put £0 as the requested salary and in the justification section, provide additional details of the funding source. The funding source must be contributing salary only (e.g., PhD scholarship) and not providing monies for any research expenses.

The justification section MUST be used to explain why the appointment is required for the project. Reference should be made to the level of experience required or held, the tasks the person will be undertaking as described in the experimental plan, a justification of the costs involved and any other necessary supporting information.

b) **Salary Costs Table**

All figures must be given in GBP (£ Sterling) and must include any on-cost or fringe benefits that the employer is legally obliged to pay and any annual increases for inflation or projected pay awards. Costs should be rounded up to the nearest GBP (£ Sterling) and written without any currency symbols, commas, full stops, points or zeros (e.g. £153,508 should be written as 153508). Grants are awarded and payments are made in GBP (£ Sterling). Figures
included in this section should be checked with your Finance Office (or equivalent) for accuracy before submission of your application.

If you are requesting funds for a PhD student, please enter the stipend along with the degree fees in the Gross Salary. Use the PhD salary/stipend and degree fee rates applicable at your institution. Within the UK, if there are no institutional rates, stipends and fees should be reimbursed at the MRC rates.

If your application is successful, you will be required to provide written evidence from your Human Resources department that details how the salary figures were calculated. This should normally be an institutional salary scale with further details of any employer's on-costs or fringe benefits such as pensions, tax, insurance or holiday pay that the institution is legally obliged to fund. This also applies to PhD fees and stipends. A grant will not be awarded unless this evidence is provided when requested.

The figures you provide will be the amounts awarded and no further increases will be made by the charity to the salary budget. It is the responsibility of the PI to make sure sufficient funds for the posts being requested are fully covered by the budget request.

Consumables
The standard consumables allowance is £15,000 per year per researcher working full time (100% committed) on the project. In exceptional circumstances, where a project requires more than one researcher, we may allow consumables to up to £30,000 per year. Excessive budget requests will be reduced without discussion and may even cause the application to be rejected.

If you are requesting the salary of a researcher who is not working full-time (100% committed) on the project, you are entitled to request the commitment % of the £15,000 per year consumables allowance. For example, if you are requesting the salary for a researcher working 60% on the project you are entitled to claim £9,000 per year (15,000 × 0.6).

You can request consumables for a full-time researcher who will be 100% committed to the project and whose salary is covered solely by another funding source. Please see the above Staff section for details.

Consumables for research positions not listed in the salaries section cannot be claimed. Consumables include non-reusable, routine items specific to the research, such as chemicals, enzymes, antibodies, molecular biology kits and reagents, glassware, plastics, dyes, radioisotopes, tissue culture costs, etc.

You must break down your consumables’ request under at least 3 general headings (using the “Add Consumable” button). For example, ‘tissue culture’, ‘PCR’, ‘immunohistochemistry’. Separate headings are created using the ‘Add Consumables’ function. It is not necessary to provide a very detailed breakdown of items and costs, but there should be some justification for the budget requested. Applications that request a flat allowance of £15,000 per year with no attempt to justify the costs will be rejected without review.

If the project requires unusual consumables or particularly large amounts or expensive types of consumables, they should be listed under “Other”. Examples include microarrays, SILAC and
fees for external or internal services, such as antibody production, DNA sequencing or statistical support.

Animals
Please ensure that you have read the full text of the Worldwide Cancer Research policy on Use of Animals in Research policy (https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/) before requesting animal costs. If you have any questions, please contact the Research Funding team (grants@worldwidecancerresearch.org) in advance.

Animal costs can include the purchase or importation of the animals, weekly charges for housing and other necessary charges (e.g., SPF or microinjection). The species of the animals and numbers should be provided, along with a full justification of the budget you are requesting. For example, give estimates of the number of animals required for each type of experiment, how many experiments of each type, the duration that the animals will need to be maintained and the cost per week per animal. Without such justification, the animal costs awarded may be reduced. The information that you provide in this section should be consistent with the information given in the Animal Research and Animal experiment details sections. Any animal costs over £10,000 must be well justified.

Equipment
Funds can be requested for small pieces of specialist or unusual equipment that are essential for the project. Small pieces of routine equipment, laptops or computers can be included only if the PI is a new group leader within the first three years of setting up their first laboratory. The only exception is for PIs who are based at an institute in a low-, middle income country (https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/daclist.htm), who can request routine equipment regardless of their seniority level.

Equipment costs should normally be included in the first year only, unless there is a good reason to purchase it later in the grant.

The justification section should be used to explain why the equipment must be purchased for the project and is not available any other way. Please consult Table 1, in this handbook, for further information on permitted equipment requests.

Travel
Travel costs and registration fees to attend conferences may be requested up to a rate of £500 per year for each person whose salary would be paid by the grant. This allowance can be allocated over the duration of the grant (e.g., £500 per annum, or the full £1500 in year 3). These costs should be itemised as ‘conference travel’ and further details provided in the justification.

We will consider further requests for travel (over and beyond the conference travel mentioned above; e.g. visits to collaborating laboratories or travel for patient and public involvement), if it is necessary for the success of the project. Itemise these requests separately from conference travel, re-using the ‘Add Travel’ function as necessary. The justification for these should indicate the reason for travel, and costs should be based on economy class fares and accommodation.

All travel funding should be made in the Travel section of the financial details page, NOT in the Other funding section.
Other
This section should be used for research items that are not included in Consumables. These costs usually fall into the following categories:

- High cost items or experiments e.g. microarrays or SILAC.
- Fees for external or internal services, such as antibody production, DNA sequencing or statistical support
- Data storage costs

Give each item and the cost separately (using ‘Add Other’) and explain why the item is necessary in the justification (e.g., cost per sample, cost per hour).

Indirect and overhead costs are not permitted under any circumstances. See section 4 for examples of ineligible costs.

7.15 Project Description page

Our grants are for discrete projects rather than research programmes with large teams of staff. You must submit a research proposal that describes a discrete project achievable within the duration of the grant and with the resources and financial support requested.

Attach a PDF document describing the research project. The following information should be given:

- Background
- Hypothesis and specific aims
- Preliminary results (if appropriate)
- Experimental plan including time scales and milestones
- Potential risks and challenges
- References (cited as: Authors, Title, Year, Journal)

Tables, images and graphs can be included but these should be kept as simple as possible (i.e., do not embed multiple tables into one image). The document must be in PDF format only and must not exceed 10 MB or 8 pages, including references.

Margins must be no less than 2cm x 2cm and Arial 10 point is the smallest font we will accept. Applications which deliberately reduce the margin size or use smaller fonts for the project description or references will be rejected. It is not in your interest to make your project proposal difficult for reviewers to read.

Please note that it is important to disclose all information in your project plan that will be necessary for a proper review of your grant. If there are commercially sensitive details, or other confidential information that you do not wish to be seen by external reviewers, you must contact us for advice before you submit your application (grants@worldwidecancerresearch.org).
7.16 Alignment with our Research Strategy

Our research strategy is very important to us at Worldwide Cancer Research. Our SAC will judge applications based on how well they align with our research strategy. Please address the four criteria: Starting new ideas, Exciting and creative, Scientific quality, and Transformative impact.

7.17 Animal research

Worldwide Cancer Research policy is to only fund research involving the use of animals when we are confident that acceptable standards of laboratory animal welfare are applied. When considering what constitutes an acceptable standard, Worldwide Cancer Research puts great emphasis on the principle of the Three R’s (Reduction, Refinement and Replacement). The full text of the Worldwide Cancer Research policy on Use of Animals in Research can be found at https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/.

If your project includes research on live animals – including invertebrates – please complete this section carefully. Information provided in this section should be consistent with that given in the Financial Details, Animals (budget request) section.

Does your project involve the use of live animals?
Yes or No. If your answer is No, you can proceed to the next page. If your answer is Yes, you will need to provide information on the species to be used.

Enter species (maximum 3)
Use the ‘Add’ option to enter the species’ details. Up to three species’ details can be entered by adding them separately.

If you add either a rodent or frog, you will have to complete the relevant questionnaire on animal welfare and attach it to your application. The questionnaire can be found at the bottom of the pop-up window once you have selected the animal species. An ‘Attach’ option is also found at the bottom of the same pop up window. Please download and complete the questionnaire before attaching it.

Animal experiment details page
If you propose to use animals protected under UK law (all vertebrates), you are required to answer some further questions on this page.

Worldwide Cancer Research is committed to ensuring that high animal welfare standards are adopted in its funded research projects which involve animal experimentation.

Please show, in your answers to the questions detailed below, what steps you have taken to implement the principles of the Three R’s in animal experimentation.

- **Replacement** – describe why there is no alternative to using animals in this research.
- **Reduction** – explain the steps you will take to keep the number of animals used to a minimum (i.e., to obtain more information from fewer animals or more information from the same number of animals).
- **Refinement** – show that you have designed your experiments to ensure that the animals used will suffer as little as possible (e.g., use of improved housing or changes to procedures which will minimise pain and suffering).

**Are any of the animals Genetically Modified?**
Yes or No

**What would be the severity of the procedures?**
More information regarding the procedures involved is required for moderate and severe procedures.

**Why is animal use necessary; are there any other possible approaches?**
State why animal use is necessary.

**Why is the species/model to be used the most appropriate? What are the sex considerations in your experimental design?**
Explain why you have chosen the species/model detailed in your project description and if both sexes are going to be used. Provide a justification if this is not the case.

**Please justify the number of animals to be used per experiment, including details of any sample size calculations and/or statistical advice sought.**
Carefully justify the number of animals to be used in the proposed experiments.

All applications that include proposals to use mammals with special protection under UK law (cats, horses, dogs and non-human primates) will undergo an additional layer of external peer review by the UK’s National Centre for the 3Rs (https://www.nc3rs.org.uk/) for an expert assessment of animal welfare.

7.18 **Intellectual Property**

**Intellectual property (IP)**
You must indicate if you or your institution has filed, is in the process of filing, or is planning to file any patents on the theme of this project.

If Yes, you must provide details of any proposed or active applications for IP. If you abandoned any applications or patents relevant to your grant proposal, please also include them.

You must indicate if there is any background IP that will be used in the research project.

If background IP will be required, please describe that background IP, and outline any restrictions on the use of the background or the arising IP. You must state who will be providing this background IP, if they have rights to the IP, and under what conditions these are provided (e.g., what is your relationship with them, did you receive this compound/assay as a gift, or is it set up as collaboration/partnership? What are the conditions linked to this?).
Where Worldwide Cancer Research funding has led directly to Intellectual Property being commercialised and licensed, we need to ensure that our interests are protected in any commercial agreements that will cover the results/data/IP stemming from the associated project. Worldwide Cancer Research will negotiate a revenue share that fairly represents the contribution of our funding. Please refer to Appendix 2: Grant Terms & Conditions for more information.

**Technology Transfer Office**

Please give the name and email address of the appropriate person to contact about the intellectual property or commercialisation of the proposed research. It is your responsibility to inform the Technology Transfer Office of your application and the Grant Terms and Conditions in Appendix 2.

### 7.19 Other Funding page

**Similar Applications**

You must declare (and give details) if an identical or similar application has been submitted elsewhere or is likely to be submitted elsewhere by the principal investigator or any of the co-applicants. If you receive more than one offer of a grant for the project, you will have to decide which to accept.

**Current Research Funding**

You **must** list all the current research funding held by the PI and all Co-applicants, including funding that has been awarded but has not yet started. This includes all core support, research grants, collaborative programmes, contracts, start-up funding, etc. We use this section to confirm that the research in your grant application has not already been funded. Please ensure that full project titles are provided in English. If this section is not completed for all applicants, the grant may be rejected without review.

**Overlap**

You must give details of any part of the research proposed in this application that overlaps or duplicates research supported by the above funding or application(s). If there is some overlap, please tell us how much (percentage overlap) and in which aims of the project.

**Previous Worldwide Cancer Research (AICR) Funding**

You must indicate (and give details) if the principal investigator and/or any Co-applicants have previously held a grant from Worldwide Cancer Research (previously known as AICR) - either as the PI or a co-applicant on that grant. Grant reference numbers are particularly helpful. You are also asked to provide a list of publications arising from this grant.

### 7.20 Attachments page

This page simply lists all the documents that you have attached to your application. Removing or changing these attachments is normally done on the page where they were originally attached. Please note that all attachments should be uploaded in PDF format, using other formats may impede the submission process.
7.21 Declaration page

Before you can submit your application, you must declare:

- that the application is complete, accurate and in accordance with policies and guidelines laid out in the Terms and Conditions and application handbook.
- that you understand that all unsubmitted applications will be permanently deleted 30 days after the submission date for this grant round
- that you have read and understood the Worldwide Cancer Research policies on Tobacco Industry Funding, Funding Animal Research, Funding Human Stem Cell Research, Open Access Publishing, Conflict of Interest and Research Funding Privacy Notice
- that the relevant ethical and/or regulatory approvals or licences necessary for the conduct of the proposed work have been granted or will be sought if the grant is awarded
- that you accept that the details contained in the application will be viewed by a third party (i.e. external peer reviewers) and are happy that the information will be shared accordingly (this may be outside the UK and European Economic Area); that you have gained permission from the others named in the application to include their personal data and have made them aware that their data will be shared accordingly
- that you agree to provide any further information that Worldwide Cancer Research may reasonably require to assess this application
- that any outputs from generative Artificial Intelligence (AI) tools in this application have been acknowledged and if used, have been used in accordance with relevant legal and ethical standards.
- that the information in the application is complete and correct to the best of your knowledge; you have checked (and printed) the PDF version* of the application and confirm that it is ready to be reviewed and assessed.

* Please note that the PDF version of the application is the version, which is sent to reviewers, so it is worth taking the time to check through it carefully.

7.22 Validation page

This page lists the parts of the application that need to be completed before it can be fully submitted. Some of these (i.e., the agreement to participate by Head of Department and Authorising Officer and the approval by Co-applicants) will require other people to act.

Once all these parts of the application have been completed, you can then:

a) Click ‘Save and Close’

b) Click ‘PDF the application’ and print a copy to check. This is the version that the reviewers will see, so you should check carefully for any omissions or errors. It is your responsibility to ensure that the PDF version of the application is correct. Please note that the lay summary is not included in the PDF of the application as this is not required for review purposes.

c) Click the ‘Submit’ option (only available during the submission window). NB: you have to go to the Validate page first – to do a final check – before the ‘Submit’ button becomes active.

Remember – after you click ‘Submit’, the submission still has to be approved by the Head of Department and Authorising Officer before the submission deadline.
Once the Head of Department and Authorising Officer have approved the application, the application will automatically be submitted. This must be done before the submission deadline. You will receive a notification email confirming that your application has been submitted.

For the avoidance of doubt:

We will not extend the deadline to allow the final approvals to be made, or because of any confusion about how the online submission process works. It is your responsibility to ensure that your grant application is completed with enough time remaining to contact the Research Funding team (grants@worldwidecancerresearch.org) if you have any difficulties with the submission process. Please remember that we are based in the UK. We cannot guarantee to respond before the submission deadline to any queries sent in the final 48 hours of the submission window, although we will try to do so.

Grant deadlines will only be extended if we accept that Worldwide Cancer Research was at fault for unreasonably delaying the submission of your grant. Technical failures of the grants system will only be accepted as a reason to extend the deadline if they are verified by the IT Company that hosts the system.
8 Appendix 2: Grant Terms & Conditions

This is the schedule referred to in the foregoing Award Agreement between Worldwide Cancer Research, [INSERT NAME OF PRINCIPAL INVESTIGATOR] and [INSERT HOST INSTITUTION]

Schedule

Part 1
This is the schedule referred to in the foregoing Award Agreement between Worldwide Cancer Research, «Lead Applicant» and «Grant Host Institution Legal Name»

Schedule

Part 1

Terms and Conditions for Research Grant Award

1. Contract

Worldwide Cancer Research is prepared to offer the Grant to the Grantholder and the Institution under the set of terms and conditions. No variation of the Award Agreement shall be valid unless in writing and signed on behalf of Worldwide Cancer Research. In the event of a conflict between the terms and conditions contained in the letter and those contained in the Schedule, the terms of the letter shall prevail.

2. Definitions

2.1. Words and expressions in these terms and conditions shall have the same meanings as attributed to them in the offer letter. Otherwise, the definitions and rules of interpretation in this clause 2 apply to these terms and conditions:

"Application" means the grant application submitted by the Lead Applicant
"Completion Date" means the date on which the Project is completed;
"Departure Date" shall have the meaning ascribed to it at clause 10.1 of these terms and conditions;
"Equipment" shall have the meaning ascribed to it at clause 4.8 of these terms and conditions;
"Grant Year" means the 12 month period from the start of the grant
"Handbook" means the Worldwide Cancer Research Project Grant Application handbook (as updated from time to time) which is available on the Website;
"Intellectual Property" means all patents, rights to inventions, utility models, copyright and related rights, trademarks, service marks, trade, business and domain names, rights in trade dress or get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database right, topography rights, moral rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications for and renewals or extensions of such rights, and all similar or equivalent rights or forms of protection in any part of the world which derive from the Project;
"Progress Report" means a scientific report on the progress made towards achieving the objectives set out in the Application (or as modified by subsequent agreement by Worldwide Cancer Research);
"Revenue Income" means any benefit including, but not limited to, any monies, shares, options or other rights arising from the commercial exploitation of the Intellectual Property generated from or arising as a result of the Project;
"Start Date" means the commencement date of the Grant as stipulated on page 1 of the Award Agreement;
"Successor Institution" means another university, research organisation or other institution the Grantholder chooses to take up an offer of employment with, upon leaving the Institution
“Website” means Worldwide Cancer Research’s website, [https://www.worldwidecancerresearch.org/](https://www.worldwidecancerresearch.org/)

2.2 Clause and paragraph headings shall not affect the interpretation of the Award Agreement

2.3 A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person’s legal and personal representatives, successors and permitted assignees.

2.4 A reference to a company shall include any company, corporation or other body corporate, wherever and however incorporated or established.

2.5 Words in the singular shall include the plural and vice versa.

2.6 A reference to one gender shall include a reference to the other gender.

2.7 A reference to a statute, statutory provision or any subordinate legislation made under a statute is to such statute, provision or subordinate legislation as amended or re-enacted from time to time and, in the case of a statute, includes any subordinate legislation made under that statute.

2.8 A reference to writing or written includes faxes and e-mail.

2.9 Any phrase introduced by the terms including, include, in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms.

3. **Provision of Grant & Conditions of Payment**

3.1 Subject to the availability of funds (and subject to clause 9 of these terms and conditions), Worldwide Cancer Research shall make available the Grant to the Grantholder on the terms of the Award Agreement for the purpose of enabling the Grantholder to carry out the Project.

3.2 Worldwide Cancer Research, the Grantholder and the Institution acknowledge and agree that the Grant creates no obligations or duties among Worldwide Cancer Research, the Grantholder and the Institution other than as set out in the Award Agreement.

3.3 The Grantholder undertakes to use his/her best endeavours to complete the Project within the time period specified in the Application or as otherwise agreed between Worldwide Cancer Research and the Grantholder and at a cost not exceeding the sum of the Grant as stipulated at page 1 of the Award Agreement. The Grantholder agrees that he/she shall not make any material change to the Project without the prior written approval of Worldwide Cancer Research.

3.4 Worldwide Cancer Research shall produce an annual budget ("the Annual Budget") which is based on the Grantholder’s budget request as stipulated in the Application. The budget shall not be increased on an annual basis and for the avoidance of doubt, there shall be no obligation on Worldwide Cancer Research to fund or reimburse any increased pay awards, bonuses, merit awards or any other changes to staff salaries.

3.5 Irrespective of the number of grant years for which the Grant is awarded, each Grant Year has a separate budget and sums allocated for each Grant Year may not be carried forward into another Grant Year.

3.6 Worldwide Cancer Research shall pay the Annual Budget to the Grantholder, quarterly in arrears, in accordance with the payment schedule set out in this Award Agreement. Following provision of an interim
reconciliation under clause 3.7.1, Worldwide Cancer Research reserves the right to adjust the Annual Budget for the following Grant Year taking into account actual spend and shall issue the Grantholder with an updated payment schedule for the following Grant Year. Payment of the Grant is subject to signature of this Award Agreement and compliance with the terms and conditions of the Award Agreement, including Annex A to the Award Letter.

3.7 Reconciliations

3.7.1 The Grantholder and/or Institution shall provide to Worldwide Cancer Research an interim reconciliation on an annual basis. Each annual interim reconciliation shall cover the period commencing on the anniversary of the Start Date (for the avoidance of doubt, for the first Grant Year this shall commence on the Start Date) through to the following anniversary of the Start Date (the 'Annual Reconciliation Period'). The Grantholder and/or Institution shall provide each annual interim reconciliation to Worldwide Cancer Research no later than three months following the end of the Annual Reconciliation Period for each Grant Year. The Grantholder and/or Institution shall provide accompanying invoices and documentation with each reconciliation and shall set out within the reconciliation form all costs based on actual expenditure, incurred by the Grantholder in carrying out the Project for the time period specified (within the limits stipulated in the Annual Budget). Any documentation provided must be in English (or an English translation provided). Worldwide Cancer Research reserves the right to suspend future payments against the Award until all documentation is received and deemed to be adequate to support the expenditure. The Grantholder and/or Institution shall also provide further interim reconciliations upon the reasonable request of Worldwide Cancer Research.

3.7.2 The Grantholder and/or Institution must also submit a final reconciliation to Worldwide Cancer Research at the end of the Grant within 3 months of the end date of the Grant and labelled clearly as the final reconciliation. The final reconciliation and any attached documentation must be provided in English (or an English translation provided) and shall detail all costs based on actual expenditure, incurred by the Grantholder in carrying out the Project.

3.7.3 The final payment of the Grant, as detailed in the payment schedule at Annex B of this Award Agreement, will only be paid following:

(i) submission of the final financial report/reconciliation by the Grantholder and/or institution;

(ii) submission of the final scientific report under clause 3.10

(iii) approval of such final report by Worldwide Cancer Research.

Following payment of the final amount by Worldwide Cancer Research, Worldwide Cancer Research shall accept no further claims or requests for payment.

3.7.4 The transfer of allocated funds between the budget headings detailed in the Application and in the Budget Breakdown (Part 2 of the Schedule), (i.e. staff costs, consumables, animals, equipment, travel and other) is not permitted under any circumstances.

3.7.5 Any overspend or underspend revealed during the reconciliation process under any budget heading will be deducted from available budget under the relevant heading in the following year (or, if such overspend or underspend occurs in the final Grant Year, Worldwide Cancer Research shall invoice the Institution for any such amount following the final reconciliation and the Institution shall pay each invoice within thirty (30) days of the date of the invoice). For the avoidance of doubt, any Grant funding which the Institution has received in accordance with Annex B but which has not been expended on the Project in its allocated Grant Year (an 'Underspend') shall not be used for expenditure in any other Grant Year and shall be claimed back by Worldwide Cancer Research through deductions to funds allocated in subsequent Annual Budget(s).

3.7.6 The transfer of allocated funds between Grant Years is not permitted, except with the prior written consent of Worldwide Cancer Research, such consent to be granted entirely at the discretion of
Worldwide Cancer Research and where the Institution can provide sufficient justification for such transfer to occur. Any grant funds which have not been spent in accordance with the Annual Budget will belong to Worldwide Cancer Research. Such remaining sums cannot be carried forward into a subsequent Grant Year.

3.8 It is the Grantholder and Institution’s responsibility to ensure that reports and reconciliations are submitted within the timescales stated. Acceptance of such is at the discretion of Worldwide Cancer Research. Failure to adhere to the terms of this Clause shall be deemed a material breach in accordance with Clause 9.3.

3.9 All figures should be entered in GBP (£ Sterling) on the reconciliation form. Payments will be remitted in GBP (£ Sterling) and converted to the currency of request by the bank at its exchange rate on the day the transfer is approved. All costs incurred relating to the transfer of funds shall be paid by Worldwide Cancer Research. The Grantholder is liable for all costs incurred in the conversion of funds from GBP (£ Sterling) to the currency of request. Worldwide Cancer Research is not responsible for losses incurred through fluctuations in exchange rates. Any actual gains made by the Grantholder and/or Institution must be used only for Activities under the Grant.

3.10 The Institution shall be responsible for repaying to Worldwide Cancer Research immediately upon receipt of a written demand by Worldwide Cancer Research any Grant funds which have been remitted to the Institution in the absence of adequate supporting documentation. Payment of Grant funds shall be made in accordance with the conditions of payment detailed in the Award Agreement and no other method of payment shall be permitted.

3.11 Continuation of grant funding shall be dependent upon the Grantholder submitting satisfactory scientific reports according to the table below. Whether a scientific report is deemed satisfactory shall be at the discretion of Worldwide Cancer Research. Final payment will be withheld pending receipt by Worldwide Cancer Research of the final report, in accordance with clause 3.7.3. Worldwide Cancer Research will also require completion of a short follow up reports three and six years after the closure of the grant.

<table>
<thead>
<tr>
<th>Period of Project to be Covered by Report</th>
<th>Report Due to be Submitted to Worldwide Cancer Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>month 1 - month 6</td>
<td>prior to grant payment at month 9</td>
</tr>
<tr>
<td>month 7 - month 18</td>
<td>prior to grant payment at month 21</td>
</tr>
<tr>
<td>month 18 – completion date</td>
<td>within 3 months after completion date</td>
</tr>
</tbody>
</table>

3.12 In the event that the Grantholder ceases to be employed by the Institution for any reason, Worldwide Cancer Research must be informed as soon as possible and shall be entitled to withhold the scheduled payment immediately preceding the Departure Date. The Institution /Grantholder shall submit a reconciliation form to Worldwide Cancer Research to enable Worldwide Cancer Research to determine the final payment prior to the transfer or termination of the Grant to a succeeding Grantholder and/or Institution. In the event of overpayment within the Grant Year, Worldwide Cancer Research shall invoice the Institution for the outstanding amount and the Institution shall pay the amount identified in any such invoice within thirty (30) days of the date on the invoice.

3.13 Where the project application submitted by the Grantholder indicates that more than one party will be involved in carrying out the research, and the Award has been granted on such a basis, Worldwide Cancer Research will pay the Grant only to the Institution. Worldwide Cancer Research shall not be liable to reimburse or make any Grant payment to more than one institution at a time and shall not in any circumstances be responsible for reimbursing or making payment to any third party institution, person or organisation involved in the Project. In the event that any third party institution is involved in the Project (other than the Institution), it shall be the responsibility of the Grantholder/Institution to allocate funds to any collaborating parties in accordance with the Annual Budget and the terms and conditions of the Award Agreement and to ensure that any third party institution is reimbursed for any expenditure incurred by it in terms of the Project and the Grantholder shall
procure that a chargeback agreement is put in place between the Grantholder, the Institution and the third party institution. Worldwide Cancer Research shall be provided with copy of such chargeback agreement immediately following its execution by all parties.

3.14 The Institution is not entitled to any additional charges such as overheads, bench fees, publication or administrative costs. The Institution may only be reimbursed for costs incurred which are within the remit of the Grant. The Institution undertakes to meet all other costs, taxes, charges and liabilities not covered by the Grant but necessary for the Grantholder to successfully carry out the Project.

3.15 The Institution shall be responsible and liable for proper financial management of the Grant and use of charitable funds, including the creation and retention of records of expenditure in connection with the Grant. The Institution shall provide such records to Worldwide Cancer Research upon request. The Institution must keep in place all procedures and security arrangements which enable it to monitor and protect against fraudulent activity, bribery, and any other illegal practices.

3.16 Worldwide Cancer Research shall be entitled to suspend payments of the Grant under the payment schedule identified in this Award Letter if:

3.16.1 The reports, reconciliations, claims and supporting documentation identified in this clause 3 have not been submitted to Worldwide Cancer Research as required;
3.16.2 the Grantholder and/or Institution has failed to maintain progress on the project to the reasonable satisfaction of Worldwide Cancer Research;
3.16.3 the Grantholder and/or Institution has breached or failed to comply with the Award Agreement (including where any collaborators of the Institution have failed to comply with such).

3.17 The Grantholder and the Institution are required to comply with Worldwide Cancer Research’s rules, policies and procedures. Our research policies can be found on the Website and concern animal research, human stem cell research, tobacco industry funding, open access publishing, conflict of interest and research funding privacy. Additional information not available on the Website may be communicated to the Grantholder and/or the Institution by Worldwide Cancer Research from time to time.

4. Staff and Equipment

4.1 The Grantholder may work on the Project independently or may opt to work on the Project in partnership with or with assistance from research workers (each of whom may or may not be receiving support from Worldwide Cancer Research in their own right). The costs incurred by the Institution as a result of the employment or engagement of the Grantholder and any research workers or staff members who are involved with the Project shall be the responsibility of the Institution. The Institution may then be reimbursed from the Grant for staff costs which are incurred through the employment or engagement of any research workers or staff members who are paid salaries from the Grant (subject to clause 4.4 and 4.7 of these terms and conditions).

4.2 Nothing in the Award Agreement shall render the Grantholder nor any research worker or staff member who is involved with the Project an employee, worker, agent or partner of Worldwide Cancer Research. The Grantholder shall not and the Institution shall ensure that any research worker or staff member who is involved with the Project shall not hold him/herself out as such.

4.3 The Institution shall be fully responsible for and indemnify Worldwide Cancer Research against any liability, assessment or claim for:

4.3.1. Taxation whatsoever arising from or made in connection with the employment or engagement of any research worker or staff member who is involved with the Project where such recovery is not prohibited by law; and
4.3.2. Any employment-related claim or any claim based on worker status (including reasonable costs and expenses) brought by the Institution or the Grantholder against Worldwide Cancer Research arising out of or in connection with the Project.

Worldwide Cancer Research may satisfy such indemnity (in whole or in part) by way of deduction from any grant payment due to be paid.

4.4 Worldwide Cancer Research will not reimburse the cost of paid maternity, paternity or adoption leave for staff who are paid salaries from the Grant. Worldwide Cancer Research will also not reimburse the cost of paid leave for any staff due to illness. Staff are employed or engaged by the Institution and it is the Institution’s responsibility to ensure that it complies with its obligations under employment law. The Institution undertakes that it will upon receipt of a written request from Worldwide Cancer Research supply to Worldwide Cancer Research the attendance records of any staff member who is paid a salary from the Grant. In the event that such attendance records show that Worldwide Cancer Research has unknowingly or mistakenly reimbursed the cost of paid maternity, paternity, adoption or sick leave for any member of staff paid a salary from the Grant, the Institution shall repay to Worldwide Cancer Research the full amount of such maternity, paternity, adoption or sick leave which has been paid by Worldwide Cancer Research.

4.5 In some instances, with the prior written consent of Worldwide Cancer Research, a Grant may be used to cover the cost of replacement staff members to take the place of staff members who are absent due to periods of maternity, paternity or adoption leave or sickness absence.

4.6 Any advertisement for research workers or other staff members to be appointed by the Institution in relation to the Project must state that the Project is funded by Worldwide Cancer Research and the Institution undertakes to disclose to Worldwide Cancer Research the details of, and any alteration to, each appointment made as soon as is practicable after the appointment.

4.7 Notwithstanding anything in this clause 4, staff expenses shall in all circumstances be limited to the amount which is detailed in the Budget Breakdown (with the exception of clause 9.1).

4.8 All equipment purchased with funds provided by the Grant (the “Equipment”) shall be the property and responsibility of the Institution. The Institution shall during the Grant period maintain the Equipment (at its own expense) in good and substantial repair in order to keep it in good operating condition including replacement of worn, damaged and lost parts, and shall make good any damage to the Equipment. Worldwide Cancer Research shall not reimburse the cost of replacement Equipment and shall not reimburse the cost of repairs to damaged Equipment.

4.9 The Institution shall not without the prior written consent of Worldwide Cancer Research part with control of (including for the purposes of repair or maintenance), sell or offer for sale, underlet or lend the Equipment or allow the creation of any mortgage, charge, lien or other security interest in respect of it.

5. Media and Publications

5.1. Subject to clause 6.1, the Grantholder and the Institution undertake to assist Worldwide Cancer Research in fulfilling its policy of publicising as widely as possible its grants and progress in scientific research supported by Worldwide Cancer Research. The Grantholder and the Institution undertake not to enter into any restrictive publication arrangements in relation to any results, data or other information connected with or arising from the Project, without the prior written consent of Worldwide Cancer Research, it being understood
that in terms of clause 6.1, certain Intellectual Property may be required to be protected and such Intellectual Property ought to remain confidential. Further, Worldwide Cancer Research will use reasonable endeavours to respect any reasonable requests from the Grantholder and/or the Institution not to publish confidential information. It is hereby agreed by the Institution and the Grantholder that:

5.1.1. The Grantholder and/or the Institution will provide Worldwide Cancer Research (by email to grants@worldwidecancerresearch.org) with an advance copy of all publications arising from the Grant within seven days of them being accepted by the publishing organisation for publication;

5.1.2. The Grantholder and the Institution will offer Worldwide Cancer Research the first right to issue a press release (or any other form of public relations material) about research publications arising from Worldwide Cancer Research-funded research where Worldwide Cancer Research funds the salary of the lead author or the Grant has funded the majority (a minimum of 51%) of the work of the publication in question. Should Worldwide Cancer Research decide not to use this right, this right will then revert to the Institution.

5.1.3. The Grantholder and the Institution will provide Worldwide Cancer Research with such photographs and other materials as reasonably requested for use on websites, fundraising, publicity and other materials;

5.1.4. Any press or media releases produced by the Grantholder and/or the Institution relating to the Project supported by the Grant will acknowledge the financial assistance given by Worldwide Cancer Research, using Worldwide Cancer Research's full title of the 'Worldwide Cancer Research', in the text.

5.2 The Grantholder and/or the Institution will provide Worldwide Cancer Research (by email to grants@worldwidecancerresearch.org) with an advance copy of any press or media releases relating to the research supported by the Grant not less than seven days before they are released by the relevant publishing medium.

5.3 Worldwide Cancer Research may use the Application (including details of staff named in the Application, their qualifications and employment history), Progress Reports, final and any interim reports in such manner as it sees fit and may copy, publish and distribute the applications and such reports or parts of them in any part of the world without payment to the Grantholder or the Institution provided that such use respects the confidential nature of any such material contained within these documents, that in doing so it acknowledges these documents as its source.

5.4 The Grantholder and the Institution will acknowledge the financial assistance given by Worldwide Cancer Research in any published documents, or presentations related to the research supported by the Grant, either in the text or in a footnote, using Worldwide Cancer Research's full title of the 'Worldwide Cancer Research'.

5.5 The Grantholder and Institution agree to be bound by the provisions of clause 5 of these terms and conditions both during the term of the Grant and after the expiration or termination of the Grant.

5.6 Worldwide Cancer Research reserves the right to publish details of the Grant, including the name of the Grantholder, the name of the Institution, the title of the Project, the grant award, biographical materials (including high resolution photographs of the Grantholder, and other lab members), and a summary of the Project on the Website, the NCRI website, the International Cancer Research Partnership website and in relevant publications.

5.7 The Institution will display a web link from its website to the Website.
5.8 The Grantholder shall, upon request, act as an external referee for Worldwide Cancer Research to help it assess other grant applications.

5.9 The Institution and/or Grantholder shall promptly supply any information relevant to the Grant that is requested by Worldwide Cancer Research.

5.10 The Worldwide Cancer Research logo (the “Trade Mark”) must be clearly visible on all presentation slides and/or paperwork, posters, handouts and laboratory websites. A copy of the current logo of Worldwide Cancer Research can be provided upon written request. Worldwide Cancer Research shall retain ownership of and all rights in the Trade Mark. The Grantholder and the Institution shall be granted a perpetual, non-transferable royalty-free licence to use the Trade Mark under the Award Agreement to the extent necessary for the purpose of fulfilling its obligations under the Award Agreement. No other rights shall be granted to the Grantholder or the Institution relating to any Intellectual Property of Worldwide Cancer Research.

6. Commercial Benefits and Patient Benefits

6.1 The Institution and/or the Grantholder shall on a continuing basis throughout the term of the Grant fully inform Worldwide Cancer Research of any results, data and/or other information arising from the Project (including any Intellectual Property rights they may contain) which might be suitable for commercial exploitation. Publication or any other form of public presentation of said results, data and/or other information should not occur until after Worldwide Cancer Research has been informed in terms of this clause 6.1 and has given its written consent to such disclosure (such consent shall not be withheld unreasonably in the event that all the necessary steps to protect any Intellectual Property rights have been taken (where reasonably appropriate) prior to such disclosure).

6.2 The Institution and the Grantholder shall use all reasonable endeavours to exploit commercially the results, data and/or other information arising from the Project in a manner conducive to maximising the patient benefit arising therefrom, except where it is otherwise agreed with Worldwide Cancer Research (either itself or through its agent) subject to clause 6.6 of these terms and conditions.

6.3 Any Revenue Income, whether effected by or derived from commercial exploitation by the Institution or Worldwide Cancer Research (either itself or through its agent), shall following reimbursement of direct costs incurred by either the Institution or Worldwide Cancer Research in carrying out the exploitation, be divided equally between the Institution and Worldwide Cancer Research (or its agent) in terms of a revenue share arrangement which will be put in place. In the case of the Grantholder leaving to join the Successor Institution the apportionment of the Revenue Income shall be agreed between Worldwide Cancer Research, the Institution and the Successor Institution before there shall be any transfer of the rights arising from the Award Agreement to the Successor Institution. In the event that the Project is not wholly funded by Worldwide Cancer Research, or where Worldwide Cancer Research is/was not the sole funder of the research from which the Intellectual Property being exploited is derived, a revenue share arrangement shall be put in place which reflects the relative contribution of all parties involved such that an equitable share of commercial rights and benefits is achieved.

6.4 Before entering into any arrangement with a third party, or commencing any procedure (including patent application) in relation to any results, data and/or information arising from the Project the Institution and/or the Grantholder shall:
6.4.1. provide, on a confidential basis to Worldwide Cancer Research (and/or its agent) in such reasonable
detail as may be requested, details of the proposals for the exploitation of the results, data and/or
information, including, where possible, details of any agreement it is proposed that the Institution and/or
the Grantholder enter into with any third party, the identity of that third party and that third party’s
intentions with regard to the use or exploitation of the results, data or information; and
6.4.2. take into account in its negotiations with third parties any representations made by Worldwide Cancer
Research, bearing in mind the legitimate interest of Worldwide Cancer Research in such negotiations
as a potential recipient of a share of the Revenue Income and, keep Worldwide Cancer Research
(and/or its agent) fully advised on a confidential basis as to the progress of such negotiations; and
6.4.3. provide on a confidential basis detailed accounts of Revenue Income and relative costs at such
frequency and in such detail as required from time to time by Worldwide Cancer Research (or its agent),
and in any case not less than once a year.

The above provisions also apply retrospectively to any arrangements entered into before the Grant was
awarded which grant rights to the results/data/Intellectual Property generated as a result of the Grant award.

6.5. The Institution shall allow Worldwide Cancer Research (or its agent), to meet and discuss with the
Grantholder any results, data and/or information arising from the Project and any potential for the protection
of any Intellectual Property and for the commercial exploitation of their research. If any of the said results,
data and/or information are deemed protectable or have potential for commercial exploitation then Worldwide
Cancer Research (or its agent) will inform the Institution. Any information provided to the Worldwide Cancer
Research or its agent shall be kept confidential until it is in the public domain.

6.6. Worldwide Cancer Research reserves the right to exploit (either itself or through its agent) the said results,
data and/or information and/or apply for patents in its own name, if and to the extent that:

6.6.1. the Institution decides not to take or does not take active steps towards protecting the Intellectual
Property and/or exploiting the same within six months of the same being documented by the Institution
and/or the Grantholder unless there is a reasonable reason for this as communicated in writing to
Worldwide Cancer Research/its agent; or

6.6.2. if prior thereto, the Institution states in writing that it does not intend to exploit the same; or

6.6.3. if the Institution agrees with Worldwide Cancer Research (or its agent) to allow Worldwide Cancer
Research (or its agent) the right to exploit the same.

6.7. In the event that any Intellectual Property arising from any results, data and/or information arising from the
Project is deemed protectable in terms of clause 6.5 above and the Institution (in the reasonable opinion of
Worldwide Cancer Research) does not take any active steps towards protecting such Intellectual Property or
does not (in the reasonable opinion of Worldwide Cancer Research) fully co-operate with Worldwide Cancer
Research’s (or its agent’s) attempts to protect such Intellectual Property, the Institution and the Grantholder
shall immediately upon request assign to Worldwide Cancer Research (or its agent), for no cost, their
respective whole right, title and interest in and to the results, data and/or other information.
The Institution and the Grantholder shall co-operate fully with Worldwide Cancer Research (or its agent) in entering into such other documents and taking such steps at the expense of Worldwide Cancer Research (or its agent) as may be reasonably necessary to allow Worldwide Cancer Research (or its agent) to exploit fully and effectively the results, data and/or other information.

7. Scientific Integrity

7.1 It shall be the responsibility of the Institution to investigate any allegation or suspicion of scientific fraud. The Grant will not be awarded to the Grantholder if the Institution is unable to produce to Worldwide Cancer Research information regarding its procedure for dealing with scientific fraud.

7.2 In the event that scientific fraud by any party to the Award Agreement or any third party who is involved in the Project is suspected or alleged during the term of the Project, the Institution shall notify Worldwide Cancer Research and keep Worldwide Cancer Research informed of all further developments. Worldwide Cancer Research reserves the right to suspend the Grant if it is of the view that the Institution is not taking adequate steps to investigate the suspicion or accusation.

7.3 In the event that an investigation by the Institution results in a case of scientific fraud being proven, Worldwide Cancer Research reserves the right to terminate the Grant immediately and to require the Institution to repay to Worldwide Cancer Research all funding which has been remitted to the Institution in terms of the Grant prior to the date on which scientific fraud was proven.

7.4 The Grantholder or the Institution may not accept any other grant or research funding to carry out the Project, or any part of it, without the prior approval of Worldwide Cancer Research, such approval not to be withheld unreasonably.

8. Research Governance

8.1. The Institution must ensure that all research, experiments and activities undertaken in relation to the Project conform with all relevant laws and regulations which apply to such activities. Such laws and regulations include, but are not limited to:

8.1.1. health and safety;
8.1.2. genetic modification;
8.1.3. the use of animals;
8.1.4. stem cells;
8.1.5. human tissue;
8.1.6. human volunteers; and
8.1.7. data protection.

8.2. The Institution and the Grantholder undertake to ensure that, at all times during the period of the Grant:

8.2.1. all research is conducted to the appropriate ethical standards;
8.2.2. all research is conducted to the appropriate scientific standards;
8.2.3. all information relating to the research is handled, stored and disseminated appropriately;
8.2.4. all appropriate health and safety regulations are enforced and followed;
8.2.5. proper financial and accounting procedures are followed; and
8.2.6. a quality research culture is fostered within the Institution.

9. Termination

9.1 Worldwide Cancer Research has the right to terminate the Grant and the Award Agreement at the end of any Grant Year by giving four weeks' prior written notice to the Grantholder and the Institution, without prejudice to the rights and duties of either party accrued prior to the date of termination. In the event that the Grant and the Award Agreement are terminated in accordance with this clause 9.1, Worldwide Cancer Research may (at its sole discretion) reimburse from the Grant any reasonable staff costs which arise from Worldwide Cancer Research’s termination of the Grant and the Award Agreement. For the avoidance of doubt, staff costs/expenses paid out in accordance with this clause 9.1 shall in all circumstances be limited to the total amount of the Grant which is outstanding at the date of termination.

9.2 In the event that the Institution wishes to terminate the Grant and the Award Agreement, it must provide the following documents to Worldwide Cancer Research:

9.2.1. four weeks' prior written notice;
9.2.2. a scientific report by the Grantholder covering the period from the end of the period covered in the previous Progress Report (which was submitted to Worldwide Cancer Research) to the date of termination; and
9.2.3. a written statement of the reasons for termination.

Termination of the Award Agreement and the Grant in terms of this clause 9.2 is at the discretion of Worldwide Cancer Research and is without prejudice to the rights and duties of each party accrued prior to the date of termination. Failure to submit the report detailed at clause 9.2.2 shall result in the final Grant payment being withheld.

9.3 Worldwide Cancer Research may at any time terminate the Award Agreement with immediate effect, with no liability to make any further payment in terms of the Grant (other than in respect of any accrued expenditure at the date of termination) if the Institution and/or the Grantholder are in material breach of any of their obligations under the Award Agreement. Any delay by Worldwide Cancer Research in exercising its rights to terminate shall not constitute a waiver of those rights.

9.4 Worldwide Cancer Research may immediately terminate the Grant and the Award Agreement in the event that:

9.4.1. any party suspends, or threatens to suspend, payment of its debts or is unable to pay its debts as they fall due or admits inability to pay its debts or (being a company) is deemed unable to pay its debts within the meaning of section 123 of the Insolvency Act 1986 or is deemed either unable to pay its debts or as having no reasonable prospect of so doing, in either case, within the meaning of section 268 of the Insolvency Act 1986; or
9.4.2. any party commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with its creditors; or
9.4.3. a petition is filed, a notice is given, a resolution is passed, or an order is made, for or in connection with 
the winding up of any party (being a company); or 
9.4.4. an application is made to court, or an order is made, for the appointment of an administrator, or if a 
notice of intention to appoint an administrator is given or if an administrator is appointed, over the other 
party (being a company); or 
9.4.5. the holder of a qualifying floating charge over the assets of that other party (being a company) has 
become entitled to appoint or has appointed an administrative receiver; or 
9.4.6. a person becomes entitled to appoint a receiver over the assets of the other party or a receiver is 
appointed over the assets of the other party; or 
9.4.7. any party (being an individual) is the subject of a bankruptcy petition or order; or 
9.4.8. a creditor or encumbrancer of any party attaches or takes possession of, or a distress, execution, 
sequestration or other such process is levied or enforced on or sued against, the whole or any part of 
that party's assets and such attachment or process is not discharged within 14 days; or 
9.4.9. any event occurs, or proceeding is taken, with respect to any party in any jurisdiction to which it is 
subject that has an effect equivalent or similar to any of the events mentioned in clause 9.4.1 to 9.4.8 
(inclusive) of these terms and conditions; or 
9.4.10. any party suspends or ceases, or threatens to suspend or cease, carrying on all or a substantial part 
of its business; or 
9.4.11. the Grantholder dies or is expelled or dismissed from the employment of the Institution and no 
suitable (in the sole opinion of Worldwide Cancer Research) alternative grantholder, arrangement or 
agreement between Worldwide Cancer Research and the Institution can be agreed in order to continue 
the Project; or 
9.4.12. there is a material change of circumstances relating to either the Institution, the Grantholder or the 
Project which (in the reasonable opinion of Worldwide Cancer Research) fundamentally changes the 
circumstances on which Worldwide Cancer Research determined to award the Grant to the Institution.

10. Change of Institution

10.1 Should the Grantholder leave the Institution in order to take up an offer of employment with another university, 
research organisation or other institution (the “Successor Institution”), the Grantholder shall seek the consent 
of Worldwide Cancer Research to the transfer of the Grant to the Successor Institution. Subject to the express 
written consent of Worldwide Cancer Research, the Successor Institution shall be free to accept and undertake 
responsibility for the continuing administration of the Project, on the terms set out in the Award Agreement 
and/or on any other terms that Worldwide Cancer Research may in its absolute discretion conclude with the 
Successor Institution. The Institution shall enter into the Novation Agreement (and shall execute any other 
paperwork required to effect the transfer of the Grant) if required to do so by Worldwide Cancer Research and 
shall, from the date stipulated in the Novation Agreement (the “Departure Date”), cease to be a party to the 
Award Agreement and shall have no further obligations to Worldwide Cancer Research in terms of the Award 
Agreement from the Departure Date. The Novation Agreement will be provided upon written request to 
Worldwide Cancer Research.

10.2 Notwithstanding clause 10.1 of these terms and conditions, the Grantholder shall remain bound by the terms 
of the Award Agreement.
10.3 The Grantholder shall give no less than six weeks’ written notice of the request to transfer the Grant to the Successor Institution to Worldwide Cancer Research prior to the Departure Date and the Grantholder shall use his or her best endeavours to procure that the Successor Institution shall enter into the Novation Agreement in relation to the transfer to it of the Institution’s rights and obligations in terms of the Award Agreement. Failure by the Grantholder to comply with this clause 10.3 shall be deemed a material breach of the agreement in terms of clause 9.4.

10.4 The Equipment shall be the property and responsibility of the Institution, but, notwithstanding clause 4.8, if the Grantholder moves to the Successor Institution and Worldwide Cancer Research has authorised the transfer of the Grant to the Successor Institution, the Equipment shall become the property and responsibility of that Successor Institution.

10.5 For the avoidance of doubt, all references in the Award Agreement to the Institution shall, with the exception of clause 6.3 of these terms and conditions, be deemed to include the Successor Institution.

10.6 In the event that Worldwide Cancer Research does not consent to the transfer of the Grant to the Successor Institution, and no suitable (in the sole opinion of Worldwide Cancer Research) alternative grantholder, arrangement or agreement between Worldwide Cancer Research and the Institution can be agreed which facilitates the continuation of the Project, Worldwide Cancer Research shall have the right to immediately terminate the Grant and the Award Agreement in accordance with clause 9.4.12 of these terms and conditions.

11. Data Protection

11.1 The Grantholder and the Institution consent to Worldwide Cancer Research holding and processing data relating to him/her/it for legal, personnel, administrative and management purposes and in particular to the processing of any “sensitive personal data” as defined in the Data Protection Act 1998 (UK). All personal data will be processed in accordance with Worldwide Cancer Research’s privacy policies, available on Website.

11.2 The Grantholder and the Institution consent to Worldwide Cancer Research making his/her/its relevant data available to those who provide products or services to Worldwide Cancer Research, regulatory authorities, governmental or quasi-governmental organisations and business contacts of Worldwide Cancer Research or any part of its business.

11.3 The Grantholder and the Institution consent to the transfer of his/her/its relevant data to Worldwide Cancer Research’s business contacts outside the European Economic Area in order to further the interests of the Grantholder and/or the Institution.

12. Miscellaneous

12.1 A waiver of any right under the Award Agreement is only effective if it is in writing and it applies only to the party to whom the waiver is addressed and the circumstances for which it is given.

12.2 If any provision of the Award Agreement is found by any court or administrative body of competent jurisdiction to be invalid, unenforceable or illegal, the other provisions will remain in force.
12.3 If any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, that provision will apply with whatever modification is necessary to make it valid, enforceable and legal.

12.4 The Award Agreement constitutes the entire agreement between the parties. The parties acknowledge and agree that (save in the case of fraud), in entering into the Award Agreement they do not rely on any undertaking, promise, assurance, statement, representation, warranty or understanding (whether in writing or not) of any person (whether party to the Award Agreement or not) relating to the subject matter of the Award Agreement other than as expressly set out in the Award Agreement.

12.5 The Grantholder and the Institution shall not, without Worldwide Cancer Research's prior written consent, assign, transfer, charge, sub-contract or deal in any other manner with all or any of the Grantholder's and the Institution's rights or obligations under the Award Agreement. Worldwide Cancer Research may at any time assign, transfer, charge, sub-contract or deal in any other manner with all or any of its rights or obligations under the Award Agreement.

12.6 Nothing in the Award Agreement is intended to, or shall operate to, create a partnership between the parties, or to authorise either party to act as agent for the other, and neither party shall have authority to act in the name of or on behalf of or otherwise to bind the other in any way, (including the making of any representation or warranty, the assumption of any obligation or liability and the exercise of any right or power).

12.7 The Award Agreement is made for the benefit of the parties to it and is not intended to benefit, or be enforceable by, anyone else.

12.8 Notice given under the Award Agreement shall be in writing, sent for the attention of the person, and to the address, given in the Award Agreement (or such other address, or person as the relevant party may notify in writing to the other party) and shall be delivered personally, sent by pre-paid, first-class post or recorded delivery. A notice is deemed to have been received, if delivered personally, at the time of delivery, in the case of pre-paid first class post or recorded delivery, 48 hours from the date of posting and, if deemed receipt under this clause 12 is not within normal business hours (meaning 8.30 am to 4.30 pm Monday to Friday on a day that is a Business Day), at 8.30 am on the first business day following delivery.

12.9 Scots law shall be the applicable law of the Award Agreement and the Scottish courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with the Award Agreement or its subject matter.
Part 2

Budget Breakdown

[INSERT NAME OF PRINCIPAL INVESTIGATOR]
Worldwide Cancer Research Grant Ref: 22-1000
[INSERT NAME OF INSTITUTION]

<table>
<thead>
<tr>
<th></th>
<th>Grant Year 1</th>
<th>Grant Year 2</th>
<th>Grant Year 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>01/01/24-31/12/24</td>
<td>01/01/25-31/12/25</td>
<td>01/01/26-31/12/26</td>
<td></td>
</tr>
<tr>
<td>STAFF COSTS</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSUMABLES</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANIMALS</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQUIPMENT</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAVEL</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHER</td>
<td>Requested</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTALS</td>
<td>£</td>
<td>£</td>
<td>£</td>
<td>£</td>
</tr>
</tbody>
</table>

Notes: These budget figures will not increase on an annual basis.